Literature DB >> 32009076

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin.

Daisaku Masuda1, Shizuya Yamashita1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32009076      PMCID： PMC7406402          DOI： 10.5551/jat.ED124

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  9 in total

Review 1.  Endothelial dysfunction.

Authors:  Dierk H Endemann; Ernesto L Schiffrin
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

Review 2.  Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus.

Authors:  M Syvänne; M R Taskinen
Journal:  Lancet       Date:  1997-07       Impact factor: 79.321

3.  Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS).

Authors:  Hirohito Sone; Sachiko Tanaka; Shiro Tanaka; Satoshi Iimuro; Koji Oida; Yoshimitsu Yamasaki; Shinichi Oikawa; Shun Ishibashi; Shigehiro Katayama; Yasuo Ohashi; Yasuo Akanuma; Nobuhiro Yamada
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

Review 5.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

6.  Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Authors:  Kenneth W Mahaffey; Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Elisa Fabbrini; Tao Sun; Qiang Li; Mehul Desai; David R Matthews
Journal:  Circulation       Date:  2017-11-13       Impact factor: 29.690

7.  Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.

Authors:  Takahiro Sawada; Kenzo Uzu; Naoko Hashimoto; Tetsuari Onishi; Tomofumi Takaya; Akira Shimane; Yasuyo Taniguchi; Yoshinori Yasaka; Takeshi Ohara; Hiroya Kawai
Journal:  J Atheroscler Thromb       Date:  2019-10-18       Impact factor: 4.928

Review 8.  Postprandial Hyperlipidemia and Remnant Lipoproteins.

Authors:  Daisaku Masuda; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2016-11-08       Impact factor: 4.928

9.  Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).

Authors:  Daisaku Masuda; Takuya Kobayashi; Masami Sairyou; Hiroyuki Hanada; Tohru Ohama; Masahiro Koseki; Makoto Nishida; Norikazu Maeda; Shinji Kihara; Tatsuya Minami; Koji Yanagi; Yasushi Sakata; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2017-12-02       Impact factor: 4.928
  9 in total
  1 in total

1.  Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy.

Authors:  Zhiqin Zhang; Lihua Ni; Lian Zhang; Dongqing Zha; Chun Hu; Lingli Zhang; Huiling Feng; Xiaobao Wei; Xiaoyan Wu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-18       Impact factor: 3.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.